Moderna, Inc. received notice that the U.S. Department of Health and Human Services (HHS) will terminate the award for the late-stage development and right to purchase influenza vaccines. In January, Moderna was awarded $590 million by the Biden administration to advance the development of its bird flu vaccine, and expansion of clinical studies for up to five additional subtypes of influenza. The HHS previously awarded $176 million to complete the late-stage development and testing of a mRNA-...